KER 065
Alternative Names: KER-065; RKER-065Latest Information Update: 05 Jan 2024
At a glance
- Originator Keros Therapeutics
- Class Obesity therapies; Recombinant fusion proteins
- Mechanism of Action Activin inhibitors; Myostatin inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Duchenne muscular dystrophy
- Preclinical Obesity